The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
E Karran, B De Strooper - Nature Reviews Drug Discovery, 2022 - nature.com
Many drugs that target amyloid-β (Aβ) in Alzheimer disease (AD) have failed to demonstrate
clinical efficacy. However, four anti-Aβ antibodies have been shown to mediate the removal …
clinical efficacy. However, four anti-Aβ antibodies have been shown to mediate the removal …
Amyloid β-based therapy for Alzheimer's disease: Challenges, successes and future
Y Zhang, H Chen, R Li, K Sterling… - Signal transduction and …, 2023 - nature.com
Amyloid β protein (Aβ) is the main component of neuritic plaques in Alzheimer's disease
(AD), and its accumulation has been considered as the molecular driver of Alzheimer's …
(AD), and its accumulation has been considered as the molecular driver of Alzheimer's …
[HTML][HTML] Two phase 3 trials of gantenerumab in early Alzheimer's disease
Background Monoclonal antibodies that target amyloid-beta (Aβ) have the potential to slow
cognitive and functional decline in persons with early Alzheimer's disease. Gantenerumab is …
cognitive and functional decline in persons with early Alzheimer's disease. Gantenerumab is …
Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial
Tau plays a key role in Alzheimer's disease (AD) pathophysiology, and accumulating
evidence suggests that lowering tau may reduce this pathology. We sought to inhibit MAPT …
evidence suggests that lowering tau may reduce this pathology. We sought to inhibit MAPT …
Guidelines on the Use of therapeutic apheresis in clinical practice–Evidence‐Based approach from the Writing Committee of the American Society for Apheresis: The …
L Connelly‐Smith, CR Alquist, NA Aqui… - Journal of clinical …, 2023 - Wiley Online Library
Abstract The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …
[HTML][HTML] Lecanemab, aducanumab, and gantenerumab—binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for …
L Söderberg, M Johannesson, P Nygren, H Laudon… - …, 2023 - Elsevier
Immunotherapy against amyloid-beta (Aβ) is a promising option for the treatment of
Alzheimer's disease (AD). Aβ exists as various species, including monomers, oligomers …
Alzheimer's disease (AD). Aβ exists as various species, including monomers, oligomers …
Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease
S Salloway, S Chalkias, F Barkhof, P Burkett… - JAMA …, 2022 - jamanetwork.com
Importance The EMERGE and ENGAGE phase 3 randomized clinical trials of aducanumab
provide a robust data set to characterize amyloid-related imaging abnormalities (ARIA) that …
provide a robust data set to characterize amyloid-related imaging abnormalities (ARIA) that …
Biomarkers for neurodegenerative diseases
O Hansson - Nature medicine, 2021 - nature.com
Biomarkers for neurodegenerative diseases are needed to improve the diagnostic workup in
the clinic but also to facilitate the development and monitoring of effective disease-modifying …
the clinic but also to facilitate the development and monitoring of effective disease-modifying …
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease
Blood‐based markers (BBMs) have recently shown promise to revolutionize the diagnostic
and prognostic work‐up of Alzheimer's disease (AD), as well as to improve the design of …
and prognostic work‐up of Alzheimer's disease (AD), as well as to improve the design of …
The amyloid cascade hypothesis: an updated critical review
Results from recent clinical trials of antibodies that target amyloid-β (Aβ) for Alzheimer's
disease have created excitement and have been heralded as corroboration of the amyloid …
disease have created excitement and have been heralded as corroboration of the amyloid …